How do you actually implement the revised EU-GMP Annex 1 in your sterile manufacturing operation?
We guide manufacturers of sterile medicinal products through the revised EU-GMP Annex 1: from building the site-wide Contamination Control Strategy (CCS) and the gap analysis against Grade A to D through to aseptic process simulation. The real lever is not the individual monitoring activity, but the CCS as a steering document. A strategy that does not connect its risks logically will not be recognised by the inspection team as a means of control, but read as a collection of SOPs.
- Pharma
- Biotech
Overview
What does the revised Annex 1 require of manufacturers?
Guiding sterile manufacturing against the revised EU-GMP Annex 1 · CCS, RABS/isolator, media fill · risk-based in line with ICH Q9
Last updated: 2026-06-13
EU-GMP Annex 1 governs the manufacture of sterile medicinal products. The 2022 revision is substantively in force since August 2023; individual requirements have only applied since 2024. For the first time it requires a site-wide Contamination Control Strategy and shifts the focus from isolated monitoring to integrated contamination risk management. The points at which implementation most often gets stuck:
- Contamination Control Strategy (CCS): The revised Annex 1 requires an overarching, site-specific strategy that links cleanroom design, personnel hygiene, material and personnel flow, cleaning and monitoring, and does not merely consolidate existing SOPs.
- Barrier technologies: Annex 1 favours isolators to separate personnel and product. RABS (Restricted Access Barrier Systems) remain possible in legacy facilities, but require a robust, risk-based justification in the CCS.
- Quality risk management in line with ICH Q9: Decisions on contamination control, for example on monitoring frequencies, validation scope and interventions, must be based on documented, scientifically sound risk management, not on convention.
- Grade A areas and aseptic interventions: Human interventions in Grade A must be reduced to the minimum and justified in the CCS; first air and continuous particle and microbiological monitoring requirements have been tightened.
- Aseptic process simulation (media fill): The requirements for failure investigation of contaminated units and for linking media fills with routine validation have been raised.
Services
How we support you
Contamination Control Strategy (CCS)
Building and implementing a site-wide CCS as the central steering document. You receive a strategy that connects cleanroom design, personnel hygiene, monitoring and cleaning with quality risk management in line with ICH Q9 and derives risks in a logically traceable way.
Gap Analysis & Inspection Readiness
A systematic review of your sterile production environment against the revised Annex 1, including classification of areas from Grade A to D. You receive a prioritised action plan to close the gaps ahead of the next inspection.
Learn more →RABS & Isolator Strategies
Support with the selection, justification and qualification of barrier systems (isolators, RABS, blow-fill-seal). You receive the procedural and technical concept, including a risk-based decision basis for new-build and retrofit projects.
Aseptic Processing & Media Fill Validation
Planning, review and evaluation of aseptic process simulations (media fills). You receive assessed filling simulation protocols, a verified sterile filter validation and Annex 1-compliant trending for environmental monitoring.
Cleanroom Qualification
Support with the qualification of Grade A to Grade D areas against the particle classification in line with ISO 14644 and the Annex 1 limits. You receive the link between qualification results and the ongoing monitoring concept.
How we work together
What it comes down to
The revised EU-GMP Annex 1 no longer requires individual measurements, but a strategy that steers those measurements. The right sequence is decisive. First, quality risk management in line with ICH Q9 establishes the scientific basis, then the facility configuration drives the decision on isolator or RABS, and only on this foundation is the Contamination Control Strategy built as a steering document that brings together cleanroom design, personnel and material flow, cleaning and monitoring. Anyone who writes the CCS before the risk assessment and the barrier decision are in place documents a current state instead of steering it.
The critical point is almost never a single requirement, but the connection between them. Grade A interventions, media fills and environmental monitoring must trace back to the same risk assessment so that a contaminated unit in the media fill is not investigated in isolation, but can be worked through against the CCS. It is precisely this traceability that the inspection team examines. A CCS whose risks do not interlock logically is read as a collection of SOPs and not recognised as a means of control.
Our approach
Our approach
Step
Result
Gap analysis
Prioritised action list: where your sterile manufacturing stands against the revised Annex 1, what is critical and what is a matter of effort.
Risk assessment (ICH Q9)
Documented, scientifically sound risk assessments as the basis for monitoring frequencies, validation scope and intervention rules.
CCS build
A site-wide Contamination Control Strategy that links design, hygiene, cleaning and monitoring logically.
Barrier & aseptic concept
A justified RABS/isolator decision and an integrated media fill and monitoring concept.
Inspection readiness
Sterile manufacturing prepared with consistent documentation and rehearsed intervention scenarios for the inspection.
Common pitfalls
Where projects commonly fail
The CCS is set up as a summary of existing SOPs.
The revised Annex 1 requires a steering strategy that connects risks logically; a mere collection of documents is not recognised as a Contamination Control Strategy in an audit.
Quality risk management in line with ICH Q9 is missing as a robust basis.
Monitoring frequencies and validation scope are set by convention instead of from documented, scientifically sound risk assessments, a recurring observation.
The RABS decision in legacy facilities remains unjustified.
Annex 1 favours isolators; whoever uses RABS must justify this on a risk basis in the CCS, otherwise a justification gap arises in the audit.
Human interventions in Grade A are neither minimised nor justified.
Interventions must be reduced to the minimum and documented in the CCS; every unjustified intervention becomes a finding.
Media fills run disconnected from routine validation.
If aseptic process simulations are not integrated with monitoring and failure investigation, the robust analysis required by the revised Annex 1 is missing when units are contaminated.
FAQ
Frequently asked questions
Sources
- EU-GMP Guide Annex 1, Manufacture of Sterile Medicinal Products (Revision 2022), primary text
- ICH Q9, Quality Risk Management
- ISO 14644, Cleanrooms and associated controlled environments
- https://theentourage.de/expertise/annex-1-sterilherstellung/ (existing page content, revised)
Life Science Journal
Regulatory updates, straight to your inbox.
New requirements, authority decisions and practice notes. Once a month, unsubscribe any time.
Case Studies
What this looks like in practice
Regulations & standards considered
- EU-GMP Guide Annex 1 (Manufacture of Sterile Medicinal Products, Revision 2022)
- ICH Q9 (Quality Risk Management)
- ISO 14644 (Cleanrooms and associated controlled environments)
Related topics
Good Manufacturing Practice (GMP) →
The overarching framework for your pharmaceutical quality system
Inspection Readiness →
Systematic preparation for inspections of sterile manufacturing
Process Validation →
Validation of aseptic processes beyond the media fill logic
GxP Audit Consulting →
Audits against GMP requirements including Annex 1 focal points
Have a concrete project?
Briefly outline your situation. We'll respond with an initial assessment, usually within one business day.
Prefer direct? +49 89 4161170-0
info@theentourage.de
- Reply usually within one working day
- 4 offices: DE · CH · IT · US
- 100% life sciences